Nuveen Asset Management, LLC Phathom Pharmaceuticals, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

A detailed history of Nuveen Asset Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 154,374 shares of PHAT stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

154,374

Previous 141,022 9.47%

Holding current value

$1.16 Million

Previous $1.45 Million 92.22%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.25 - $19.5 $136,858 - $260,364	13,352 Added 9.47%	154,374 $2.79 Million
Q2 2024 Aug 09, 2024	SELL	$8.97 - $12.05 $1.09 Million - $1.46 Million	-121,026 Reduced 46.18%	141,022 $1.45 Million
Q1 2024 May 13, 2024	SELL	$6.21 - $11.05 $264,303 - $470,299	-42,561 Reduced 13.97%	262,048 $2.78 Million
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $117,257 - $179,660	16,775 Added 5.83%	304,609 $2.78 Million
Q3 2023 Nov 14, 2023	BUY	$10.26 - $15.7 $1.09 Million - $1.67 Million	106,225 Added 58.49%	287,834 $2.98 Million
Q2 2023 Aug 14, 2023	BUY	$7.28 - $14.32 $533,806 - $1.05 Million	73,325 Added 67.72%	181,609 $2.6 Million
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $2,209 - $4,412	357 Added 0.33%	108,284 $773,000
Q4 2022 Feb 14, 2023	SELL	$9.18 - $11.53 $88,605 - $111,287	-9,652 Reduced 8.21%	107,927 $1.21 Million
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $13,152 - $24,655	2,036 Added 1.76%	117,579 $1.3 Million
Q2 2022 Aug 15, 2022	BUY	$6.2 - $15.5 $334,564 - $836,411	53,962 Added 87.63%	115,543 $976,000
Q1 2022 May 16, 2022	BUY	$11.55 - $20.06 $15,742 - $27,341	1,363 Added 2.26%	61,581 $823,000
Q4 2021 Feb 14, 2022	SELL	$17.83 - $33.15 $167,191 - $310,847	-9,377 Reduced 13.47%	60,218 $1.18 Million
Q3 2021 Nov 12, 2021	SELL	$30.69 - $36.83 $751,598 - $901,966	-24,490 Reduced 26.03%	69,595 $2.23 Million
Q2 2021 Aug 16, 2021	BUY	$32.66 - $39.87 $918,693 - $1.12 Million	28,129 Added 42.65%	94,085 $3.19 Million
Q1 2021 May 17, 2021	BUY	$33.86 - $48.68 $99,887 - $143,606	2,950 Added 4.68%	65,956 $2.48 Million
Q4 2020 Feb 16, 2021	BUY	$33.22 - $50.26 $44,348 - $67,097	1,335 Added 2.16%	63,006 $2.09 Million
Q3 2020 Nov 16, 2020	BUY	$29.24 - $40.19 $340,148 - $467,530	11,633 Added 23.25%	61,671 $2.26 Million
Q2 2020 Aug 14, 2020	BUY	$25.06 - $54.6 $364,522 - $794,211	14,546 Added 40.98%	50,038 $1.65 Million
Q1 2020 May 14, 2020	BUY	$24.65 - $42.83 $3,623 - $6,296	147 Added 0.42%	35,492 $916,000
Q4 2019 Feb 14, 2020	BUY	$18.59 - $37.67 $657,063 - $1.33 Million	35,345 New	35,345 $1.1 Million

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $294M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Phathom Pharmaceuticals, Inc. Transaction History